

Intellia Therapeutics Corporate Responsibility Report

Publication date: April 2024

TABLE OF CONTENTS

- [Our Corporate Responsibility Commitment](#)
- [About Intellia](#)
- [Commitment to Patients](#)
- [Commitment to Our Employees](#)
- [Commitment to Our Environment and Local Communities](#)
- [Commitment to Information Security](#)
- [Commitment to Corporate Governance](#)
- [Intellia Awards](#)
- [Contact Information](#)
- [SASB Reporting](#)
- [Legal Disclaimer](#)

Our Corporate Responsibility Commitment

Intellia's objective is to build a sustainable company delivering on our commitment to the patients we serve, our employees, community, environment and shareholders.

We believe Environmental, Social and Governance (ESG) principles support long-term value creation. Throughout this report, we have highlighted our approach to managing risk and taking advantage of opportunities in key ESG areas – the areas that are most relevant to the long-term sustainability of our company.

About **Intellia**



Intellia
THERAPEUTICS

About Intellia

Intellia Therapeutics, a leading clinical-stage genome editing company, is developing novel, potentially curative therapeutics leveraging CRISPR-based technologies.

Our focus is on developing CRISPR-based therapies to treat patients with genetic diseases, cancer and autoimmune conditions. Our work is not only important for the patients living with these often debilitating and life-threatening diseases, but also for the families, friends and caregivers who provide their invaluable support.

At Intellia, our team of dedicated scientists work tirelessly to harness our proprietary genome editing technology for human therapeutic use—technology enabled by the pioneering work of Drs. Jennifer Doudna, an Intellia co-founder, and Emmanuelle Charpentier, co-recipients of the 2020 Nobel Prize in Chemistry.

As part of our core strategy, we are employing a modular technology platform allowing us to leverage the learnings from one program to the next and advance a diverse and growing pipeline of both *in vivo* and *ex vivo* investigational therapies.

We hope to change the future of medicine with our CRISPR-based therapies.

Intellia is Leading a New Era of Medicine

Turning Nobel-Prize-Winning Science into Medicine

- Poised to bring first-ever *in vivo* CRISPR therapy to market
- Initiated first-ever, pivotal Phase 3 program for an *in vivo* CRISPR therapy
- On track for second *in vivo* Phase 3 program in 2024

100+ patients
dosed with Intellia's
investigational *in vivo*
CRISPR-based therapies

**Robust pipeline of
in vivo and *ex vivo* programs**

**Comprehensive
gene editing toolbox**

Intellia's Core Values

Our values are at the heart of our company's identity and culture.

ONE

One is respect for individuals and our unique qualities, strengths and experiences; our own ways to understand, learn and improve. **One** is our single-minded determination to excel and to succeed together. **One** is trust and relying on every one of us to triumph.

EXPLORE

Explore because we seek new ways to tackle disease. **Explore** to open our minds to be free from assumptions and be open to new ideas. **Explore** by staying curious and pushing boundaries. **Explore** means thinking of new ways to overcome obstacles.

DISRUPT

Disrupt by thinking courageously to create a better future. **Disrupt** by defying conformity and interrogating the status quo. **Disrupt** with challenging thoughts and using skepticism and imagination to develop innovative solutions.

DELIVER

Deliver by focusing on the objective and your determination to complete the task. **Deliver** by advancing relentlessly and by maintaining high standards. **Deliver** by staying accountable and pulling your weight. **Deliver** because patients are counting on us to make the promise a reality.

Commitment to
Patients



Commitment to Patients

Every day, more than 500* team members come to work at Intellia. We are motivated by our mission to develop potentially curative genome editing treatments for people living with severe diseases. Conventional medicines treat the symptoms instead of the cause of conditions, meaning that patients must be treated throughout their lives. We are working to develop one-time treatments that target the root cause of disease.

“Many of us pursuing work in the biotechnology industry are inspired by the loss of a loved one or someone in our community who is living with a disease.”



Intellia President and CEO
John Leonard, M.D.

Patients are counting on us



Nancy lives with transthyretin amyloidosis with polyneuropathy (ATTRv-PN).



Milton lives with transthyretin amyloidosis with cardiomyopathy (ATTR-CM).



Shanna lives with hereditary angioedema (HAE).

* As of April 29, 2024

Patient Stories

Meet Nancy, Shanna and Milton – all living with genetic diseases that drive us to do what we do every day. Their strength inspires us, energizes us and compels us to work urgently to address unmet medical needs. [Read their stories.](#)

We are committed to ensuring the patient voice informs our research and development, by engaging with patients through:

- Patient focus groups
- Patient speakers at employee Town Halls
- Patient stories, photos and videos on our website and social media



Nancy, living with ATTRv-PN



Shanna, living with HAE




Milton, living with ATTR-CM

Commitment to Patient Advocacy

We are proud to work closely with a number of leading patient organizations, so we can better understand the needs of patients, their families and caregivers. These relationships and collaborations allow us to hear the patient voice and help inform our decisions.

Here are some of the advocacy organizations we have relationships with who help support patients and raise awareness for transthyretin (ATTR) amyloidosis and hereditary angioedema (HAE):



Ethical Conduct, Clinical Trial Principles and Diversity, Equity and Inclusion in Clinical Trial Studies

Ethics in Clinical Studies

At Intellia, we recognize the importance of clinical research in developing potentially curative genome editing treatments for people living with severe diseases. We are committed to conducting clinical trials in accordance with the highest ethical, scientific and safety standards to ensure we are protecting the health and welfare of the individuals who enroll in our clinical trials. This is true for our research conducted internally and in partnership with external organizations. Our clinical research complies with Good Clinical Practice (GCP) guidelines and regulations issued by relevant regulatory bodies such as the EU European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA).

Clinical trial participants must provide informed consent before they are entered into a trial. Patients are provided an Institutional Review Board (IRB) or Ethics Committee (EC) approved Informed Consent Form that explains the details of the trial, including its possible risks and benefits. Participation in a clinical trial is always voluntary and participants may withdraw at any time and for any reason.

Monitor the Safety and Quality of our Products

We are committed to creating high quality products in compliance with current Good Manufacturing Practices. We protect patient safety by identifying, assessing, managing, and reporting adverse events and product quality complaints in a timely manner and as required by applicable laws and regulations. This data is used to provide accurate and up-to-date safety information to regulatory authorities, and potentially healthcare providers (“HCPs”) and patients. This information is critical to improving our products, helping us track issues for investigation and ultimately, maintaining our commitment to patients. Intellia personnel who become aware of a product quality issue or adverse event are obligated to report it using established procedures. To help us meet this commitment, Intellia has adopted an Adverse Event Reporting Policy with detailed reporting requirements.

Diversity, Equity and Inclusion (DEI) in Clinical Trials

Our aim is to sponsor inclusive clinical trials that represent the diversity of the people living with the disease who may benefit from the treatment being developed. We recognize diverse populations may be impacted differently by the same disease or may have varying responses to the same treatment. We aim to work with communities to increase health literacy and awareness of clinical trials. We will build trusting relationships and collaborate with partners to improve access to our clinical research and investigational treatments. For ATTR amyloidosis, HAE and alpha-1 antitrypsin deficiency (AATD)-associated lung disease, we are partnering closely with patient advocacy groups to engage with patients that represent the breadth of the population we aim to serve.

Commitment to External Stakeholders

Global Policy on Interactions with External Stakeholders

Intellia recognizes that our external stakeholders, including healthcare professionals (HCPs), healthcare organizations, patients, caregivers, and patient organizations, are uniquely positioned to understand the needs of patients, the performance of medicines in the clinical setting and unmet patient needs. Therefore, we are committed to working with these external stakeholders in a manner that does not have, or appear to have, any undue influence on medical judgment, treatment recommendations, or clinical trial outcomes. To ensure our commitment to the highest standards of ethics and integrity, Intellia has adopted a Global Policy on Interactions with external stakeholders to govern Intellia's interactions - including its activities related to research and development, medical engagement, and new product planning.

Clinical Trial Data Disclosure

Intellia is committed to sharing information about our clinical research and clinical trials in a responsible manner. We also support data transparency that advances science and medicine, protects participant privacy, and is in the best interest of patients and healthcare providers. Intellia-sponsored clinical trials are registered on clinicaltrials.gov, a searchable database maintained by the U.S. National Institutes of Health. Our trials are also registered on the EU Clinical Trials Information System ([CTIS](https://clinicaltrials.eu)) and comply with applicable laws and regulations.

Expanded Access Policy

Intellia is committed to solving the complex challenges of making CRISPR-based therapies a reality for patients suffering from severe and life-threatening genetic diseases. In these efforts, Intellia is guided by ethical, scientific and legal principles, which require well-designed and controlled clinical trials to evaluate the safety and efficacy of our potential therapies.

Under certain circumstances, a person suffering a serious or life-threatening disease may ask to use an experimental treatment outside a clinical trial before its safety and efficacy have been fully evaluated, and before the regulatory authorities have approved it. Generally, this is an option only for patients who have exhausted all available medical options and do not qualify for ongoing clinical trials.

The U.S. Food and Drug Administration (FDA) explains such “expanded access” as follows:

Expanded access is a potential pathway for a patient with an immediately life-threatening condition or serious disease or condition to gain access to an investigational medical product (drug, biologic, or medical device) for treatment outside of clinical trials when no comparable or satisfactory alternative therapy options are available.

Intellia appreciates the intent of expanded access programs. At this time, we do not provide access to our investigational therapies outside of clinical trials. In our view, we can best advance the development of these potential promising products by enrolling patients in clinical trials. Our clinical trials are designed, conducted and monitored to ensure that the safety and effectiveness of our experimental therapies are properly evaluated before they are made available generally. To view a list of Intellia’s open clinical trials, visit clinicaltrials.gov.

As the pace of innovation advances, particularly in the field of gene editing, Intellia is committed to regularly reviewing, and updating as needed, its policy on expanded access. As part of this pledge, a committee of senior leaders at Intellia has been established to assess both the progress of our clinical programs as well as any changes in the treatment landscape and external environment that may necessitate an adjustment to our expanded access policy. Additionally, we consult with patient organizations, external bioethicists and clinical experts to help inform our expanded access approach. Through this work, we look to balance immediate patient needs with our ability to conduct clinical trials and address the logistical and technical considerations of providing broader access to our investigational gene editing medicines.

Current Clinical Trial Footprint

Intellia is conducting ongoing clinical trials for two investigational therapies:

- NTLA-2001 for Transthyretin (ATTR) Amyloidosis
- NTLA-2002 for Hereditary Angioedema (HAE)

DOSED > 100 PATIENTS ACROSS EARLIER FIRST-IN-HUMAN STUDIES

NTLA-2001

- Currently enrolling MAGNITUDE, a global pivotal Phase 3 study in participants with hereditary (ATTRv-CM) or wild-type cardiomyopathy (ATTRwt-CM). For more information, visit clinicaltrials.gov.
- Intellia is actively preparing for a global pivotal Phase 3 study of NTLA-2001 for the treatment of ATTRv-PN.

NTLA-2002

- Recently completed enrolling the Phase 1/2 study. For more information, visit clinicaltrials.gov.
- Global pivotal Phase 3 trial anticipated to begin in the second half of 2024.

Commitment to
Our Employees



Commitment to Our Employees

Investing in our employees' professional career growth and personal wellbeing is an important priority at Intellia. We provide a wide range of learning opportunities that help our employees gain on-the-job experiences, learn through and with each other, and upskill through in-person, virtual and formal training programs.

We believe employees at all levels are leaders at Intellia

Leadership Competencies and Career Ladders are clearly defined to help our employees understand their individual career journey. We offer a variety of training programs that support our employees at every level. This starts with our New Employee Orientation Program, which provides new hires with the information they need to integrate and be successful. We offer Development Days and mentorship opportunities focused on education, learning new skills and showcasing different career paths. As part of these initiatives, programming is tailored to the topics of interest identified by employees. Internal job opportunities are highlighted to promote job mobility. Annually, our employees work with their managers to set professional development goals and an action plan. Our goal is to ensure employees have the necessary skills to meet their job current responsibilities while developing new abilities for the future.

Fostering leadership is fundamental

We invest in developing the next wave of people managers at the company. Our New Manager Orientation and Manager Effectiveness programming, as well as both Leadership and VP forums, aim to refine managerial skills in the areas of coaching for performance, development planning and leadership.

Commitment to equitable pay

We are committed to equitable pay, irrespective of race, color, religion, gender, national origin, age, sexual orientation, marital or veteran status, disability, or any other legally protected status, and conduct routine comprehensive pay-equity analyses.

Employee “SpeakUp” Line

Intellia’s SpeakUp Policy is designed to protect employees and support Intellia’s commitment to integrity and ethical behavior.

At the core of Intellia’s values, we seek to foster a culture where employees feel comfortable with open, direct and honest communication with their managers and peers. In the event employees would prefer to report an incident anonymously, employees can call or email the “SpeakUp Line” which Intellia has established for receipt of questions and concerns over any Intellia activity that may be inconsistent with any law, regulation, our policies or our Code of Business Conduct and Ethics.

The SpeakUp Line is managed by a third-party required to maintain the anonymity of the caller if so requested. Any report or complaint received is reviewed and addressed in a timely manner. In addition, reports are provided to the Audit Committee of the Board of Directors on a quarterly basis.



Commitment to Our Employees - Benefits



87% of premiums covered through Blue Cross Blue Shield MA, **100%** vision insurance



100% company-funded life insurance, short- and long-term disability through Sun Life



A competitive 401k match, FSA for dependents and free parking or a subsidy for your commute

Intellia employees enjoy:

- ✓ Company-sponsored social events
- ✓ Employee-led clubs and teams
- ✓ Family planning benefit
- ✓ Immigrant sponsorship
- ✓ Travel assistance
- ✓ Education assistance
- ✓ Employee Stock Purchase Plan (ESPP)
- ✓ Free drinks and snacks
- ✓ Periodic on-site vaccination clinics and health screening
- ✓ Tuition reimbursement
- ✓ Employee assistance program
- ✓ 401K match
- ✓ Free onsite gym
- ✓ Quarterly on-site financial advisor 1:1s
- ✓ Reproductive Health Program
- ✓ Pet Insurance
- ✓ Company-wide shutdowns
- ✓ Employee concierge program

Diversity, Equity and Inclusion (DEI)

We're dedicated to championing a culture that celebrates diversity and fosters collaboration inside the organization and in our community.

Intellia's core values include working together as one with respect for individuals, our unique qualities, strengths and our own ways to understand, learn and improve. Through our partnerships, we build key relationships in our community and help pave the way for those wanting to pursue a career in the biotechnology industry. We are committed to increasing representation of underrepresented minorities at Intellia, particularly in leadership roles. Our recruiting team undergoes bias awareness training, and we have sponsored career fairs and conferences at organizations focused on underrepresented minorities to ensure we continue to attract the best talent and increase representation. Additionally, Intellia employees participate in unconscious bias training throughout the year.

PROGRAMS WE SPONSOR:



Cultural Ambassadors

Many of our employees actively participate as an **Intellia Cultural Ambassador**, fostering a grassroots approach to engagement with support and guidance from our leadership team. We regularly get together to learn, help the greater Boston community, celebrate our diversity and get to know one another.

Our Cultural Ambassador programs aim to align our workforce around our core values and consist of the following themes: diversity, equity and inclusion, continuous learning, wellness and sustainability, social events and community outreach.

Cultural Ambassador Teams



Community Events



Diversity, Equity and Inclusion



Learning and Engagement



Wellness and Sustainability



Social Events

Employee Resource Groups





In 2023, we expanded our DEI efforts with the launch of Employee Resource Groups (ERGs). ERGs are voluntary, employee-led groups focused on fostering a diverse, inclusive workplace aligned with ONE Intellia. They are led and participated in by employees who share a characteristic, whether it's gender, ethnicity, religious affiliation, lifestyle or interest. The groups exist to provide support and help in personal or career development, and to create a safe space where employees can bring their whole selves to the table. Allies are also invited to join the ERG to support their colleagues.

ERG Activities


- "Nice Girls Don't Get the Corner Office" Book Club
- Women's History Month Panel Discussion
- STEMatch Career Day for Boston Public Schools
- Women's Equality Day Awareness
- Pride Month Celebration
- Trevor Project Fundraiser
- Parenting in the Digital World
- Caregiver Reflections

Diversity of Our Senior and Executive VPs and Employees

SENIOR AND EXECUTIVE VPs



EMPLOYEES



We're up to date with our EEO-1 reporting

Promoting the Employee Voice

We regularly gather insights from our employees around what is important to them, what we can improve and how we can continue to ensure Intellia is a great place to work.

Several Intellia initiatives have come out of this insight gathering, such as expanded family planning benefits, a formal peer-to-peer recognition program and refreshed leadership competencies by level.

The Results of Our Efforts

96%

of employees are **proud to work for Intellia**

93%

of employees said their job makes them feel like they are **part of something meaningful**

92%

of employees agreed that Intellia operates by **strong values**

Intellia's Employee Referral Program

Top talent attracts top talent. We designed our employee referral program to highlight the brilliant minds Intellia employees bring into the organization.

Referrals are and always will be our most valued source of hire.



41%

of new hires were introduced to the job opening by an employee referral

37%

of employees submitted at least 1 referral applicant in 2023

A photograph of three young women, likely students, working in a laboratory. They are wearing white lab coats, safety glasses, and gloves. The woman on the left is wearing a black face mask and has a name tag that says "Lidiane". The woman in the middle has a name tag that says "Angie". The woman on the right has a name tag that says "Tynoya". They are all smiling and looking at a large clear plastic bowl on the table in front of them. They appear to be conducting an experiment or a practical activity. There are various lab supplies on the table, including a small bottle and a pipette.

Commitment to
**Our Environment and
Local Communities**

Commitment to Our Environment and Local Communities

We take our responsibility as a member of our local community seriously. Through our Cultural Ambassadors Program and other initiatives, our employees volunteer to serve and fundraise for homeless shelters, community beautification projects and educational initiatives, particularly STEM mentoring initiatives in underserved communities. In addition, we have partnered with the United Negro College Fund and established an Intellia scholarship for college students from underrepresented groups pursuing life science majors.



Our **Wellness & Sustainability team** celebrates Earth Day annually to promote green initiatives and spread knowledge on how to live a green life.

Although, we currently have a small ecological footprint, we believe we can make a difference in protecting our environment. We invest in variable flow fume hoods, ENERGY STAR lab freezers, GreenPak™ pipette tips, recyclable batteries and fluorescent and LED bulbs.

Environmental Sustainability at Intellia

Energy Efficient Buildings



Reduction efforts with the installation of beverage machines that reduce or eliminate aluminum can or pod usage

Composting services and removal of plasticware


Recycling Programs



Single-stream recycling at our 2nd largest building

Dual-stream recycling at all other buildings

Transportation Benefits



Non-automobile transportation benefits

Access to electric vehicle charging stations

Sample of Intellia's Community Connections in 2023

Our employees frequently participate in a variety of community volunteering and donation programs.

15+

charitable organizations in 2023, with over **100** employees volunteering in various service projects



350

science experiment kits were assembled to support girls looking to work in STEM careers


\$70K+

corporate and employee donations



2

blood donation drives through Massachusetts General Hospital



30+

students were hosted from The LEAH Project for a career panel, networking session and lab tour

Select Community Partnerships

Community Volunteering

- The LEAH Project
- Science Club for Girls
- Waltham Fields Community Farm
- East End House Food Pantry
- Fenway Victory Gardens
- Biomedical Science Careers Program
- CASPAR Emergency Services Center & Shelters
- Esplanade Association
- Rosie's Place



Intellia employees partnered with CASPAR to cook dinner at their homeless shelter



Intellia employees volunteering to pack STEM kits for Science Club for Girls

A woman with dark hair, wearing a green sweater and a gold necklace, is looking at a computer monitor in an office cubicle. The cubicle wall behind her has a sign that says "BOSS TO ROCK". In the background, another person is working at a desk with a computer monitor. The office environment is modern and professional.

Commitment to
Information Security

Commitment to IT Security

Oversight, Accountability and Training

Intellia built a cybersecurity program that includes several layers of oversight. A Big Four accounting firm performed a cybersecurity maturity assessment in February 2023. We also have penetration testing performed by a cyber consulting firm annually.

The Board's Audit Committee is updated semi-annually on Intellia's cybersecurity program maturity and informed about material security incidents. The full Board is updated at least one per year on our overall cybersecurity program. Internally, the Risk Oversight and Compliance Committee (ROCC) establishes the framework for assessing risk and compliance for Intellia. Cybersecurity maturity and security incidents are discussed every other month with the IT Steering Committee.

New hires are required to attend cybersecurity training as part of their onboarding. We require annual cybersecurity training for all full-time employees, consultants, contractors, service providers and other users who have access to Intellia systems.

Information Governance and Privacy

Intellia formed an information governance group to set guidelines and expectations for handling of one of Intellia's most critical assets – our information. The Information Governance Group is led by our head of IT and routinely reports to ROCC. Our Data Classification Guidelines explain how to handle categories of information. In 2023, we continued to mature our privacy program by appointing a Privacy Officer and publishing a Global Privacy Policy.

Reducing Risks with Suppliers and Supply Chain

We strongly value our vendor relationships as we believe they have been a key factor in our long-term success. We established a third-party risk management program, where we assess and monitor risks with new and existing vendors. As part of our commitment to continuous improvement, we also use industry-standard frameworks and tools when monitoring our suppliers for certain high-risk profile changes.

Commitment to Cybersecurity

Risk management and strategy

We face a number of cybersecurity risks in connection with our business and recognize the growing threat within the general marketplace and our industry. To help the Company address these risks, we implemented a cybersecurity risk management program that is informed by recognized industry standards and frameworks and incorporates elements of the same, including elements of the National Institute of Standards and Technology Cybersecurity Framework.

Our cybersecurity risk management program includes several components, including but not limited to a Cybersecurity Incident Response Plan (“CSIRP”), annual cybersecurity awareness training for our employees, vendor risk management, regular system maintenance including application of security patches as appropriate, penetration tests and security assessments, and implementation of enhancements to security measures used to protect our systems and data.

We maintain a CSIRP that is designed to guide our incident response process for cybersecurity incidents that could affect our systems, network, or data. The CSIRP identifies the individuals responsible for developing, maintaining, and following appropriate procedures to identified cybersecurity incidents. We periodically test our CSIRP using tabletop exercises with the goal of improving our processes and preparedness.

Risks from cybersecurity threats have not to date materially affected us, including our business strategy, results of operations or financial condition.

Commitment to
Corporate Governance



Commitment to Corporate Governance

Good corporate governance is important to ensure Intellia is managed for the long-term benefit of our stockholders.

Our [Code of Business, Conduct and Ethics](#) applies to all officers, directors and employees. We have established committee charters for the [Audit Committee](#), [Nominating and Corporate Governance Committee](#), [Compensation and Talent Development Committee](#), and [Science and Technology Committee](#).



Commitment to Operating with Integrity

At Intellia, while our scientific advancements and clinical results largely define our success, how we achieve these results are of equal importance.

We require that all our employees review and adhere to a core set of compliance and behavioral policies.

In addition, our management team reviews these policies regularly and make adjustments, as needed.

As of the date of this report, Intellia updated the following internal policies, which all employees are required to read, acknowledge, and adhere to:

- **CODE OF BUSINESS CONDUCT AND ETHICS**
- **GLOBAL POLICY ON INTERACTIONS WITH EXTERNAL STAKEHOLDERS**
- **INSIDER TRADING POLICY**
- **GLOBAL PRIVACY POLICY**
- **SPEAK UP POLICY**
- **CONFLICTS OF INTEREST POLICY**
- **CONFIDENTIALITY & TRADE SECRETS POLICY**
- **VENDOR GIFTS & ENTERTAINMENT POLICY**
- **ANTI-BRIBERY & ANTI-CORRUPTION POLICY**
- **IT-INFORMATION SECURITY POLICY**
- **IT-ACCEPTABLE USE POLICY**
- **EMPLOYEE HANDBOOK**



Board of Directors At-a-Glance

63 years

Average age
of Board member

4 years

Average tenure
on Intellia's Board



6 of 7
Directors are
independent

Board of Directors - Commitment to Diversity

We believe that diversity among directors, including race, ethnicity, sexual orientation and gender, as well as experience, is an important attribute of a well-functioning board of directors and a measure of sound corporate governance.

Our Third Amended and Restated Corporate Governance Guidelines affirm our commitment to increasing our Board's diversity.



The Board of Directors includes the value of seeking diversity in considering whom to elect or nominate for membership in the Board of Directors. In evaluating director candidates, including directors eligible for reelection, the Nomination and Corporate Governance Committee considers factors that include character, integrity, judgment, diversity with respect to age, gender, ethnicity, race, nationality and sexual orientation, independence, skills, education, expertise, business acumen, business experience, length of service, understanding of the Company's business and industry, conflicts of interest and other commitments.

Our Board of Directors racial/ethnic diversity is currently 14%. In an effort to further support our goal of increased board diversity, we will continue to recruit for open seats on the board of directors and have engaged a third-party search firm to help us identify and recruit qualified candidates with diverse characteristics ranging from age, disability, gender identity or expression, ethnicity, military veteran status, national origin, race, religion, sexual orientation, and other backgrounds and experiences.

Intellia Awards



Contact Information

Corporate Headquarters

40 Erie Street
Cambridge, MA 02139

Investor contact
ircontact@intelliatx.com

Investor website
<https://ir.intelliatx.com>

SEC filings
<https://ir.intelliatx.com/financial-information/sec-filings>

Annual reports
<https://ir.intelliatx.com/financial-information/annual-reports>

Governance guidelines
<https://ir.intelliatx.com/static-files/dca3f8f4-d606-42fb-afd5-36b3dffc1308>

Clinical trial contact
clinicalscience@intelliatx.com

Careers page
<https://www.intelliatx.com/careers/>

SASB Reporting

SASB Reporting

The Sustainability Accounting Standards Board (SASB) framework aims to provide a comparable, consistent and transparent manner for communicating corporate disclosure of ESG factors. Here, we have reported Intellia's alignment to all metrics in the SASB biotechnology and pharmaceuticals framework.

SASB Topic/Code	Accounting Metric	Disclosure
HC-BP-210a.1	Discussion, by world region, of management process for ensuring quality and patient safety during clinical trials	See page 16
HC-BP-210a.2	Number of FDA Sponsor Inspections related to clinical trial management and pharmacovigilance that resulted in: (1) Voluntary Action Indicated (VAI) and (2) Official Action Indicated (OAI)	None
HC-BP-210a.3	Total amount of monetary losses as a result of legal proceedings associated with clinical trials in developing countries	None
HC-BP-240a.1	Description of actions and initiatives to promote access to health care products for priority diseases and in priority countries as defined by the Access to Medicine Index	Not applicable - Intellia is a pre-commercial company
HC-BP-240a.2	List of products on the WHO List of Prequalified Medicinal Products as part of its Prequalification of Medicines Programme (PQP)	Not applicable - Intellia is a pre-commercial company
HC-BP-240b.1	Number of settlements of Abbreviated New Drug Application (ANDA) litigation that involved payments and/or provisions to delay bringing an authorized generic product to market for a defined time period	None
HC-BP-240b.2	Percentage change in: (1) average list price and (2) average net price across U.S. product portfolio compared to previous year	Not applicable - Intellia is a pre-commercial company
HC-BP-240b.3	Percentage change in: (1) list price and (2) net price of product with largest increase compared to previous year	Not applicable - Intellia is a pre-commercial company

SASB Reporting

SASB Topic/Code	Accounting Metric	Disclosure
HC-BP-250a.1	List of products listed in the Food and Drug Administration's (FDA) MedWatch Safety Alerts for Human Medical Products database	Not applicable - Intellia is a pre-commercial company
HC-BP-250a.2	Number of fatalities associated with products as reported in the FDA Adverse Event Reporting System	Not applicable - Intellia is a pre-commercial company
HC-BP-250a.3	Number of recalls issued, total unites recalled	Not applicable - Intellia is a pre-commercial company
HC-BP-250a.4	Total amount of product accepted for takeback, reuse or disposal	Not applicable - Intellia is a pre-commercial company
HC-BP-250a.5	Number of FDA enforcement actions taken in response to violations of current Good Manufacturing Practices (cGMP), by type	None
HC-BP-260a.1	Description of methods and technologies used to maintain traceability of products throughout the supply chain and prevent counterfeiting	Not applicable - Intellia is a pre-commercial company
HC-BP-260a.2	Discussion of process for alerting customers and business partners of potential or known risks associated with counterfeit products	Not applicable - Intellia is a pre-commercial company
HC-BP-260a.3	Number of actions that led to raids, seizure, arrests and/or filing of criminal charges related to counterfeit products	Not applicable - Intellia is a pre-commercial company
HC-BP-270a.1	Total amount of monetary losses as a result of legal proceedings associated with false marketing claims	Not applicable; Any material legal proceedings are disclosed in Intellia's 10-K
HC-BP-270a.2	Description of code of ethics governing promotion of off-label use of products	Please see page 16

SASB Reporting

SASB Topic/Code	Accounting Metric	Disclosure
HC-BP-330a.1	Discussion of talent recruitment and retention efforts for scientists and research and development personnel	See commitment to our employees
HC-BP-330a.2	(1) Voluntary and (2) involuntary turnover rate for: (a) executives/senior managers, (b) midlevel managers, (c) professionals, and (d) all others	Within the biotech industry standard
HC-BP-430a.1	Percentage of (1) entry's facilities and (2) Tier 1 suppliers' facilities participating in the Rx-360 International Pharmaceutical Supply Chain Consortium audit program or equivalent third-party audit programs for integrity of supply chain and ingredients	Not applicable
HC-BP-510a.1	Total amount of monetary losses as a result of legal proceedings associated with corruption and bribery	None. Any material legal proceedings are disclosed in Intellia's 10-K
HC-BP-510a.2	Description of code of ethics governing interactions with health care professionals	See page 16

SASB Topic/Code	Activity Metric	Disclosure
HC-BP-000.A	Number of patients treated	>100 patients dosed with investigational CRISPR-based therapies
HC-BP-000.B	Number of drugs (1) in portfolio and (2) in research and development (Phases 1-3)	See our pipeline

Forward-Looking Statements - Safe Harbor

This report contains “forward-looking statements” of Intellia Therapeutics, Inc. (“Intellia”, “we” or “our”) within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements regarding our beliefs and expectations about the advancement, expansion, modularity and acceleration of our CRISPR-based platform technology and our *in vivo* and *ex vivo* pipeline to develop genome editing therapies across a variety of indications; our ability to replicate or apply results achieved in preclinical or clinical studies in any future studies; our ability to ensure that our clinical trials are conducted in accordance with the highest ethical, scientific and safety standards and that data are generated, documented and reported in compliance with the protocol, Good Clinical Practice standards defined by the International Conference on Harmonization (ICH) guidance, and the applicable regulatory requirements; our ability to ensure the proper handling of Intellia's information and that our cybersecurity and privacy programs would prevent a breach involving our information; and our ability to recruit and retain employees and directors, including diverse employees and directors, to execute our long-term strategy. Any forward-looking statements in this report are based on management’s current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. For a discussion of these risks and uncertainties, and other important factors, any of which could cause Intellia’s actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in Intellia’s most recent annual report on Form 10-K and quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in Intellia’s other filings with the Securities and Exchange Commission. All information in this report is as of the date of the report, and Intellia undertakes no duty to update this information unless required by law.

Intellia

THERAPEUTICS